产碳青霉烯酶肺炎克雷伯菌 KPC-39 介导对头孢他啶-阿维巴坦的耐药性。
KPC-39-Mediated Resistance to Ceftazidime-Avibactam in a Klebsiella pneumoniae ST307 Clinical Isolate.
机构信息
Team Resist, UMR1184, Immunology of Viral, Auto-Immune, Hematological, and Bacterial Diseases, INSERM, Université Paris-Saclay, CEA, LabEx LERMIT, Faculty of Medicine, Le Kremlin-Bicêtre, France.
Associated French National Reference Center for Antibiotic Resistance: Carbapenemase-Producing Enterobacteriaceae, Le Kremlin-Bicêtre, France.
出版信息
Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0116021. doi: 10.1128/AAC.01160-21. Epub 2021 Oct 4.
Abstract
Resistance to the ceftazidime (CAZ)-avibactam (AVI) combination is increasingly being reported. Here, we report a CAZ-AVI-resistant Klebsiella pneumoniae strain belonging to the high-risk sequence type 307 (ST307) clone and producing Klebsiella pneumoniae carbapenemase 39 (KPC-39), a single-amino-acid variant of KPC-3 (A172T). Cloning experiments, steady-state kinetic parameters, and molecular dynamics simulations revealed a loss of carbapenemase activity and increased affinity for CAZ. KPC-39 was identified in a patient without prior exposure to CAZ-AVI, suggesting silent dissemination in European health care settings.
摘要
对头孢他啶（CAZ）-阿维巴坦（AVI）联合用药的耐药性日益受到关注。在此，我们报告了一株属于高风险序列型 307（ST307）克隆的 CAZ-AVI 耐药肺炎克雷伯菌，该菌产生肺炎克雷伯菌碳青霉烯酶 39（KPC-39），是 KPC-3 的单一氨基酸变异体（A172T）。克隆实验、稳态动力学参数和分子动力学模拟揭示了碳青霉烯酶活性的丧失和对 CAZ 的亲和力增加。在未接触 CAZ-AVI 的患者中发现了 KPC-39，提示其在欧洲医疗机构中存在隐匿传播。
相似文献
1
KPC-39-Mediated Resistance to Ceftazidime-Avibactam in a Klebsiella pneumoniae ST307 Clinical Isolate.产碳青霉烯酶肺炎克雷伯菌 KPC-39 介导对头孢他啶-阿维巴坦的耐药性。
Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0116021. doi: 10.1128/AAC.01160-21. Epub 2021 Oct 4.
2
Impact of Ceftazidime-Avibactam Treatment in the Emergence of Novel KPC Variants in the ST307-Klebsiella pneumoniae High-Risk Clone and Consequences for Their Routine Detection.头孢他啶-阿维巴坦治疗对 ST307 型肺炎克雷伯菌高危克隆中新出现的 KPC 变异体的影响及其对其常规检测的后果。
J Clin Microbiol. 2022 Mar 16;60(3):e0224521. doi: 10.1128/jcm.02245-21.
3
Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.中国耐碳青霉烯类肺炎克雷伯菌中头孢他啶/阿维巴坦耐药的出现。
Clin Microbiol Infect. 2020 Jan;26(1):124.e1-124.e4. doi: 10.1016/j.cmi.2019.08.020. Epub 2019 Sep 5.
4
Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in -Harboring Klebsiella pneumoniae Sequence Type 307 Isolates.携带blaKPC-2 的肺炎克雷伯菌序列型 307 分离株通过不同的基因组适应性连续出现头孢他啶-阿维巴坦耐药性。
Antimicrob Agents Chemother. 2018 Feb 23;62(3). doi: 10.1128/AAC.02101-17. Print 2018 Mar.
5
Suboptimal drug exposure leads to selection of different subpopulations of ceftazidime-avibactam-resistant Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae in a critically ill patient.药物暴露不足导致危重症患者中产头孢他啶-阿维巴坦耐药肺炎克雷伯菌碳青霉烯酶肺炎克雷伯菌的不同亚群选择。
Int J Infect Dis. 2021 Dec;113:213-217. doi: 10.1016/j.ijid.2021.10.028. Epub 2021 Oct 14.
6
Efficacy of ceftazidime-avibactam in various combinations for the treatment of experimental osteomyelitis due to Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae.头孢他啶-阿维巴坦联合用药治疗产碳青霉烯酶肺炎克雷伯菌（KPC）导致实验性骨髓炎的疗效。
Int J Antimicrob Agents. 2023 Jan;61(1):106702. doi: 10.1016/j.ijantimicag.2022.106702. Epub 2022 Dec 5.
7
Increased Expression and Amplification of Contributes to Resistance to Ceftazidime/Avibactam in a Sequence Type 11 Carbapenem-Resistant Klebsiella pneumoniae Strain.序列型 11 碳青霉烯类耐药肺炎克雷伯菌中 表达和扩增增加导致对头孢他啶/阿维巴坦耐药。
Microbiol Spectr. 2022 Aug 31;10(4):e0095522. doi: 10.1128/spectrum.00955-22. Epub 2022 Jul 28.
8
Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering.碳青霉烯酶 2（KPC-2），在 Ambler 位置 Asp179 的取代以及对头孢他啶-阿维巴坦的耐药性：β-内酰胺酶蛋白质工程产生独特的抗生素耐药表型。
mBio. 2017 Oct 31;8(5):e00528-17. doi: 10.1128/mBio.00528-17.
9
Emergence of transferable ceftazidime-avibactam resistance in KPC-producing Klebsiella pneumoniae due to a novel CMY AmpC β-lactamase in China.中国产碳青霉烯酶肺炎克雷伯菌中新型 CMY AmpCβ-内酰胺酶导致可转移头孢他啶-阿维巴坦耐药性的出现。
Clin Microbiol Infect. 2022 Jan;28(1):136.e1-136.e6. doi: 10.1016/j.cmi.2021.05.026. Epub 2021 May 24.
10
Generating Genotype-Specific Aminoglycoside Combinations with Ceftazidime/Avibactam for KPC-Producing .针对产 KPC 肠杆菌科细菌，生成头孢他啶/阿维巴坦联合用药的基因型特异性方案
Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0069221. doi: 10.1128/AAC.00692-21.
引用本文的文献
1
Evaluation of phenotypic and genotypic methods for detecting KPC variants.检测KPC变体的表型和基因型方法评估。
Antimicrob Agents Chemother. 2025 May 7;69(5):e0008225. doi: 10.1128/aac.00082-25. Epub 2025 Apr 3.
2
Characteristic of KPC-12, a KPC Variant Conferring Resistance to Ceftazidime-Avibactam in the Carbapenem-Resistant ST11-KL47 Clone Background.KPC-12的特性，一种在耐碳青霉烯类的ST11-KL47克隆背景中赋予对头孢他啶-阿维巴坦耐药性的KPC变体。
Infect Drug Resist. 2024 Jun 20;17:2541-2554. doi: 10.2147/IDR.S465699. eCollection 2024.
3
Outbreak of NDM-5-producing ST307: an emerging high-risk antimicrobial resistance clone in Shanghai, China.产 NDM-5 的 ST307 爆发：中国上海出现的一种新的高风险抗微生物药物耐药克隆。
mSystems. 2024 Apr 16;9(4):e0136923. doi: 10.1128/msystems.01369-23. Epub 2024 Mar 20.
4
carbapenemase variants: the new threat to global public health.碳青霉烯酶变体：对全球公共健康的新威胁。
Clin Microbiol Rev. 2023 Dec 20;36(4):e0000823. doi: 10.1128/cmr.00008-23. Epub 2023 Nov 8.
5
Emergence of KPC-134, a KPC-2 variant associated with ceftazidime-avibactam resistance in a ST11 clinical strain.KPC-134的出现，一种与ST11临床菌株中头孢他啶-阿维巴坦耐药相关的KPC-2变体。
Microbiol Spectr. 2023 Sep 29;11(5):e0072523. doi: 10.1128/spectrum.00725-23.
6
Clinical Characteristics and Outcome of Ceftazidime/Avibactam-Resistant Carbapenemase-Producing Infections: A Retrospective, Observational, 2-Center Clinical Study.产碳青霉烯酶的头孢他啶/阿维巴坦耐药感染的临床特征及转归：一项回顾性、观察性、双中心临床研究
Open Forum Infect Dis. 2023 Jun 30;10(7):ofad327. doi: 10.1093/ofid/ofad327. eCollection 2023 Jul.
7
β-Lactamase Genes without Limits.不受限制的β-内酰胺酶基因。
Microorganisms. 2023 May 4;11(5):1200. doi: 10.3390/microorganisms11051200.
8
Emergence and clonal dissemination of KPC-3-producing Pseudomonas aeruginosa in China with an IncP-2 megaplasmid.产 KPC-3 型铜绿假单胞菌的出现与克隆传播及其携带的 IncP-2 型大型质粒
Ann Clin Microbiol Antimicrob. 2023 Apr 29;22(1):31. doi: 10.1186/s12941-023-00577-z.
9
Performance of Ceftazidime-Avibactam 30/20-μg and 10/4-μg Disks for Susceptibility Testing of and Pseudomonas aeruginosa.头孢他啶-阿维巴坦30/20μg和10/4μg纸片用于肺炎克雷伯菌和铜绿假单胞菌药敏试验的性能
Microbiol Spectr. 2023 Feb 6;11(2):e0272022. doi: 10.1128/spectrum.02720-22.
10
Identification of KPC-112 from an ST15 Klebsiella pneumoniae Strain Conferring Resistance to Ceftazidime-Avibactam.从一株对头孢他啶-阿维巴坦耐药的 ST15 肺炎克雷伯菌中鉴定出 KPC-112。
mSphere. 2022 Dec 21;7(6):e0048722. doi: 10.1128/msphere.00487-22. Epub 2022 Nov 14.
本文引用的文献
1
Molecular analysis of clinical isolates of ceftazidime-avibactam-resistant Klebsiella pneumoniae.头孢他啶-阿维巴坦耐药肺炎克雷伯菌临床分离株的分子分析。
Clin Microbiol Infect. 2021 Jul;27(7):1040.e1-1040.e6. doi: 10.1016/j.cmi.2021.03.001. Epub 2021 Mar 26.
2
KPC-53, a KPC-3 Variant of Clinical Origin Associated with Reduced Susceptibility to Ceftazidime-Avibactam.KPC-53，一种源自临床的KPC-3变体，对头孢他啶-阿维巴坦敏感性降低。
Antimicrob Agents Chemother. 2020 Dec 16;65(1). doi: 10.1128/AAC.01429-20.
3
Emerging Antimicrobial-Resistant High-Risk Klebsiella pneumoniae Clones ST307 and ST147.出现的具有抗药性的高风险肺炎克雷伯菌克隆株 ST307 和 ST147。
Antimicrob Agents Chemother. 2020 Sep 21;64(10). doi: 10.1128/AAC.01148-20.
4
Emergence of New Non-Clonal Group 258 High-Risk Clones among Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Isolates, France.产碳青霉烯酶肺炎克雷伯菌中新非克隆群 258 高危克隆的出现，法国。
Emerg Infect Dis. 2020 Jun;26(6):1212-1220. doi: 10.3201/eid2606.191517.
5
Substrate Specificity of OXA-48 after β5-β6 Loop Replacement.OXA-48 β5-β6 环替换后的底物特异性。
ACS Infect Dis. 2020 May 8;6(5):1032-1043. doi: 10.1021/acsinfecdis.9b00452. Epub 2020 Mar 19.
6
Ceftazidime-Avibactam Resistance Associated with Increased Gene Copy Number Mediated by pKpQIL Plasmid Derivatives in Sequence Type 258 .头孢他啶-阿维巴坦耐药与 258 型序列型中由 pKpQIL 质粒衍生物介导的基因拷贝数增加有关。
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.01816-19.
7
Impact of anticancer chemotherapy on the extension of beta-lactamase spectrum: an example with KPC-type carbapenemase activity towards ceftazidime-avibactam.抗癌化疗对β-内酰胺酶谱扩展的影响：以对头孢他啶-阿维巴坦具有 KPC 型碳青霉烯酶活性为例。
Sci Rep. 2020 Jan 17;10(1):589. doi: 10.1038/s41598-020-57505-w.
8
Different phenotypic expression of KPC β-lactamase variants and challenges in their detection.KPC β-内酰胺酶变体的不同表型表达及其检测面临的挑战。
J Antimicrob Chemother. 2020 Mar 1;75(3):769-771. doi: 10.1093/jac/dkz508.
9
Use of carbapenems in the combined treatment of emerging ceftazidime/avibactam-resistant and carbapenem-susceptible KPC-producing Klebsiella pneumoniae infections: Report of a case and review of the literature.碳青霉烯类药物联合治疗新出现的头孢他啶/阿维巴坦耐药和碳青霉烯类敏感产 KPC 肺炎克雷伯菌感染的应用：1 例病例报告及文献复习。
J Glob Antimicrob Resist. 2020 Sep;22:9-12. doi: 10.1016/j.jgar.2019.11.007. Epub 2019 Nov 13.
10
Phenotypic, biochemical and genetic analysis of KPC-41, a KPC-3 variant conferring resistance to ceftazidime-avibactam and exhibiting reduced carbapenemase activity.KPC-41的表型、生化和遗传分析，KPC-41是KPC-3的一种变体，对头孢他啶-阿维巴坦耐药且碳青霉烯酶活性降低。
Antimicrob Agents Chemother. 2019 Sep 9;63(12). doi: 10.1128/AAC.01111-19. Epub 2019 Sep 16.
Zotero 插件